Zenith Technologies sees 400% China growth in latest Asia success

22 May 2019

Company plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.

Zenith Technologies, a world leader in delivering manufacturing software solutions to the life sciences industry, has reported 400% growth in its Chinese operations in the last 3 years.

Zenith Technologies sees 400% China growth in latest Asia success
L-R Liang Zhou, General Manager China on the left and Trevor Marshall, Global Engineering Director.

The company now has a presence working on sites across five Chinese cities – Shanghai, Suzhou, Xi’an, Hangzhou & Guangzhou - and employs a growing team to work across its client base supporting pharma and biotech companies with the implementation of technologies to improve manufacturing efficiencies such as automation, IT, manufacturing execution systems (MES) and digital and data analysis.

With the Chinese life sciences market currently set as the world’s second largest national market, and with an expected value of $220 billion by 2022, Zenith plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.

Liang Zhou, General Manager of Greater China said: “The Chinese market has been leading the way in revolutionary cell therapy innovations, which are changing the face of medicine delivery. There is growing interest in the adoption of automating processes in this area as companies build a new generation of facilities in line with stringent international standards with a view to supplying across the world.

“We are well placed to support clients here who would like to adopt these solutions and have already played an integral role in the development of technologies to oversee these key cell therapy innovations.”

Zenith’s success in China represents the company’s latest endeavour in the Asian market having first set up a presence on the continent in 2002 with the opening of its regional headquarters in Singapore.

In 2008 the company set up an office in India, which now hosts more than 100 employees and serves as a global support hub to deliver software projects anywhere in the world, featuring a remote engineering centre and 24/7 IT support desk service.

Across the continent, Zenith now has a total workforce of more than 200 professionals and is actively looking to new Asian markets to expand its footprint to support the burgeoning number of life science hubs.

Bryan McSwiney, Asia Director said: “After more than 15 years in the Asian market, a quarter of our global operations are now based here and the latest growth figures from China demonstrate that we go from strength to strength.

“We now have an established presence in five Chinese cities – a significant footprint within a relatively short space of time – as well as a thriving support hub in India and a widely recognised HQ in Singapore.

“With a solid foundation now firmly established in the Asian market, we look forward to building on our successes and working closely with local and multinational companies on the continent who can benefit from the diverse range of technologies we can introduce into manufacturing facilities.”

Read More

Related news

GSK partners with Samsung Biologics to secure additional manufacturing capacity

GSK partners with Samsung Biologics to secure additional manufacturing capacity

26 May 2020

The agreement will initially cover the commercial production of Benlysta (belimumab) with the intention to expand to additional specialty-care products in the future.

Read more 
Changes needed to prevent controversial pay-for-delay pharma deals

Changes needed to prevent controversial pay-for-delay pharma deals

26 May 2020

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Read more 
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

26 May 2020

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Read more 
AbCellera and Lilly seal multi-year antibody discovery collaboration

AbCellera and Lilly seal multi-year antibody discovery collaboration

25 May 2020

AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

Read more 
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

25 May 2020

The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

Read more 
Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more